Search clinical trials for: 18F-Fludarabine

Total 4041 results

Nantes University Hospital
Cyceron

Not yet recruiting

Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients (Myelofludate)

Myeloma

France
University Hospital, Caen
CNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, France

Completed

Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies (FLUDATEP)

Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients

France
Merck Sharp & Dohme LLC

Completed

[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment
Massachusetts General Hospital
Cedars-Sinai Medical Center; ALS Association; The Methodist Hospital Research...

Completed

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis (TRACK-ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States
British Columbia Cancer Agency

No longer available

18F-FDOPA PET in Neuroendocrine Tumours

Thyroid Cancer, Medullary | Neuroblastoma | Pheochromocytoma | Carcinoid Tumor | Paraganglioma | Insulinoma

Canada
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation in Europe

Alzheimer's Disease

Netherlands
Frederick Daniel Grant
Dana-Farber Cancer Institute

Completed

FLT-PET Imaging of Brain Tumors in Children

Brain Neoplasms

United States
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
Markus Weber
University Hospital Inselspital, Berne; ETH Zurich

Not yet recruiting

Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS) (18F-RoSMALS)

Amyotrophic Lateral Sclerosis

Switzerland
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Alzheimer's Disease

France, Italy, United States
Chang Gung Memorial Hospital

Unknown

Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination (PMPBB3/AV45)

Alzheimer's Disease

Taiwan
Mayo Clinic
Blue Earth Diagnostics, Inc

Recruiting

18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain

Metastatic Intracranial Malignant Neoplasm | Recurrent Intracranial Neoplasm

United States
University of California, San Francisco
Avid Radiopharmaceuticals; Alzheimer's Drug Discovery Foundation

Recruiting

Effects of Brain Beta-Amyloid on Postoperative Cognition

Postoperative Cognitive Dysfunction

United States
GeoVax, Inc.
Emory University; Stanford University; Thomas Jefferson University

Recruiting

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

Recurrent Head and Neck Cancer

United States
Tammie L. S. Benzinger, MD, PhD

Recruiting

F 18 T807 Tau PET Imaging of Alzheimer's Disease (T807IND)

Alzheimer Disease

United States
Washington University School of Medicine

Enrolling by invitation

F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) (AV ADAD)

Alzheimer Disease

United States
Tammie L. S. Benzinger, MD, PhD

Completed

F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E) (Protocol E)

Alzheimer Disease | Progressive Posterior Cortical Dysfunction (PPCD)

United States
Avid Radiopharmaceuticals

Withdrawn

18F-AV-1451 PET Imaging in TBI

Traumatic Brain Injury

United States
Tammie L. S. Benzinger, MD, PhD

Completed

F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected

Alzheimer Disease | HIV

United States
Tammie L. S. Benzinger, MD, PhD

Withdrawn

F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 High Resolution Autopsy Study

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Terminated

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

Frontotemporal Dementia | Alzheimer's Disease

United Kingdom
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Recruiting

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

Dementia | Alzheimer Disease | Mild Cognitive Impairment

United States, Canada
Avid Radiopharmaceuticals

Completed

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy

United States
Avid Radiopharmaceuticals

Completed

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation

Alzheimer Disease

United States
Tammie L. S. Benzinger, MD, PhD

Withdrawn

Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers. (Protocol_Z)

Alzheimer Disease

United States
University Hospital Inselspital, Berne

Active, not recruiting

Diagnostic Accuracy and Performance of 18F-PSMA-1007

Prostate Cancer

Switzerland
GlaxoSmithKline
Cambridge University Hospitals NHS Foundation Trust

Terminated

A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques

Arthritis, Rheumatoid

United Kingdom
Avid Radiopharmaceuticals

Completed

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects (MCI)

Alzheimer's Disease

United States
Tammie L. S. Benzinger, MD, PhD

Completed

F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis (T807ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States
Institute for Neurodegenerative Disorders

Completed

A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions (FPEB)

Parkinson Disease | Alzheimer Disease | Mild Cognitive Impairment | Fragile X Syndrome | Huntington Disease | Autistic Spectrum Disorders

United States
Avid Radiopharmaceuticals

Completed

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Progressive Cognitive Decline

United States
Avid Radiopharmaceuticals
National Institute of Neurological Disorders and Stroke (NINDS); National Institutes...

Completed

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

Parkinson's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Physician Training Methods to Read Florbetapir-PET Scans

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Reader Training Processes

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans

Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment
Avid Radiopharmaceuticals

Completed

Evaluation of PET Scan Timing Relative to AV-45 Injection Time

Alzheimer's Disease
Avid Radiopharmaceuticals

Completed

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

A Study of 18F-AV-45 in Healthy Volunteers

Alzheimer Disease

United States
Zhejiang University

Completed

18F-FAPI PET Imaging in Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma | Diagnosis | Staging | 18F-FDG | 18F-FAPI

China
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Completed

Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)

Mild Cognitive Impairment (MCI) | Alzheimer's Disease (AD) | Significant Memory Concern (SMC) | Early Mild Cognitive Impairment (EMCI) | Late Mild Cognitive Impairment (LMCI)

United States, Canada

Search clinical trials for: 18F-Fludarabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations